About Contact Us Careers

Pharyngitis Treatment Market Size & Share Analysis, by Route of Administration (Oral, Parenteral); Drug Class; Disease Type - SWOT Analysis, Competitive Strategic Insights, Regional Trends 2026-2035

  • Report ID: 3124
  • Published Date: Sep 09, 2025
  • Report Format: PDF, PPT

Pharyngitis Treatment Market Outlook:

Pharyngitis Treatment Market size was valued at approximately USD 2.37 billion in 2025 and is projected to reach around USD 2.50 billion by the end of 2035, rising at a CAGR of 3.9% during the forecast period 2026-2035. In 2026, the industry size of the pharyngitis treatment is estimated USD 2.46 billion.

The research and development in the pharyngitis treatment market are undergoing rapid changes and surpassing regular antibiotic-based therapies. There is a need for precise diagnostics with the burgeoning burden of the Group A Streptococcus (GAS) infections. Various innovative strategies are gaining traction that aim to prevent the colonization of the GAS. The molecular PCR tests are being upgraded for better results, and the AI-enabled tools are reshaping the management of patients. These types of research and development activities highlight the transition toward preventive strategies.  

Additionally, the supply chain of the market is formed around a multi-tiered network and ensures the development of the various novel therapies. The suppliers of the raw materials render active APIs, such as derivatives of penicillin. Contract Research Organizations also play a crucial role in clinical development and implementing various regulatory compliance. Upstream supply chain delays, especially from China following recent regulatory audits, have affected downstream production cycles, driving producer prices higher. The supply chain for the pharyngitis treatment is also evolving from the conventional antibiotic-centric flow to a digitally integrated patient-centric delivery model.

Pharyngitis Treatment Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Rising healthcare spending: The rising healthcare spending is a prominent driver fueling the growth of the market. The rising spending is enhancing access to modern therapies while also propelling clinical research. The surge in allocation of resources for primary care is also confirming the broader reach. According to data published by the World Economic Forum in 2021, the global spending on health amounted to USD 9.8 trillion, accounting for more than 10.2% of the worldwide GDP. Additionally, budget realignments under CMS's Outpatient Prospective Payment System (OPPS) and Medicaid's extended formulary support have increased prescription volume and enhanced market penetration, particularly in public health institutions.
  • Rising cases of pharyngitis and associated infections: The cases of the Group A Streptococcus are increasing as a global burden with rising pollution and allergen exposure. According to data published by the National Institutes of Health in 2022, almost 288.5 million cases of Strep A sore throat occur among children aged 5-14 years. The rising number of patients with infections is ensuring that there will be a consistent necessity for antibiotics and various other supportive drug therapies. These factors are augmenting the market growth during the forecast period.
  • Advancements in diagnostic technologies: There has been an increased shift towards the precise and rapid treatments that amalgamate technologies.  Researchers and medical practitioners are emphasizing explicitly distinguishing between bacterial and viral types of pharyngitis, which is imperative to eradicate the misuse of antibiotics. According to the American Medical Association in February 2025, nearly 2/3rd of medical practitioners are using AI in healthcare services. The surge in utilization of state-of-the-art diagnostic solutions is advancing the diagnostic processes and further acting as a catalyst for the targeted treatments. The application of AI is speeding up the adoption of precision medicine and opening a plenty of opportunities for the market players.

Challenges

  • Pediatric formulations reimbursement gaps: The pharyngitis treatment’s pediatric version often seems to be lagging in full reimbursement in several countries. Further, manufacturers are not interested in investing in customized pediatric drug development without any assurance of reimbursement support, slowing down the innovation process and limiting pediatric access to essential care.

Pharyngitis Treatment Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

3.9%

Base Year Market Size (2025)

USD 2.37 billion

Forecast Year Market Size (2035)

USD 2.50 billion

Regional Scope

  • North America (U.S., and Canada) 
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific) 
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) 
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America) 
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa) 
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Pharyngitis Treatment Market Segmentation:

Route of Administration Segment Analysis

The oral segment is projected to lead the market, registering 68% of the revenue share by 2035. This rise in growth is mainly attributed to its cost-effectiveness, convenience, and widespread trends in prescription. Oral antibiotics for bacterial pharyngitis, such as amoxicillin and azithromycin, are in the first-line treatments, while NSAIDs like ibuprofen are preferred for viral cases.  The parenteral segment is limited in hospital settings to severe infections. Further, the growth in telemedicine is boosting demand for oral drugs, with plenty of prescriptions issued digitally.

Disease Type Segment Analysis

Bacterial pharyngitis drives the pharyngitis treatment market and is expected to have a share of 60% by 2035. This rise is mainly due to the treatment demand, primarily due to Group A Streptococcus infection requiring antibiotics. the rapid diagnostic tests are minimizing the use of antibiotics. By increasing treatment precision and stewardship initiatives, emerging point-of-care diagnostics may help further segment the market. These factors are augmenting the market growth exponentially during the assessed time period and offer lucrative opportunities for the market players.

Drug Class Segment Analysis

The antibiotics segment is set to garner 37% of the share by 2035, owing to the high prevalence of bacterial pharyngitis. Also, beta-lactams are manufactured on a wide level, mainly in the fast-growing markets such as China and India. Also, the rising adoption of rapid antigen tests aids in more precise segregation between viral and bacterial cases of pharyngitis. In the advanced countries with state-of-the-art healthcare infrastructure, antibiotics benefit from the robust coverage of the insurance and favorable reimbursement policies. These factors are further strengthening the position of the segment as a pioneering treatment modality.

Our in-depth analysis of the global market includes the following segments: 

Segment

        Subsegment

Route of Administration
  • Oral
  • Parenteral

Drug Class
  • Antibiotics
  • Penicillin
  • Cephalosporins
  • Macrolides
  • NSAIDs
  • Corticosteroids

Disease Type 
  • Bacterial Pharyngitis
  • Viral Pharyngitis
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Pharyngitis Treatment Market - Regional Analysis

North America Market Insights

North America dominates the pharyngitis treatment market and is expected to hold a market share of 33.8% by 2035. The market growth in this region is especially driven by high diagnostic rates, easy reimbursement structures, and leading pharmaceutical manufacturing. The key drivers are expanded Medicaid/Medicare reimbursements, government-led antimicrobial resistance (AMR) initiatives, and rising investments in pediatric care. In the U.S., NIH and CDC both emphasize early treatment adoption and preventive awareness. The region shows a rising trend in e-prescriptions, telehealth integration, and pharmacy automation, further strengthening treatment access. 

The pharyngitis treatment market in the U.S. is experiencing consistent growth, mainly supported by the insurance coverage expansions and government-backed public health programs. According to data published by the Centers for Disease Control and Prevention in August 2025, group A strep pharyngitis is considered to be the most common in children between the ages of 5 and 15 years. Also, in recent years, the spending from Medicare and Medicaid has increased significantly and further fueling the market growth during the coming period.

Asia Pacific Market Insights

The APAC market is expected to grow significantly by 2035, and is anticipated to capture a 24.7% share of the global market revenue. The growth in the region is fueled by increasing rates of infection, increased access to healthcare, and robust government interference in major economies. Increased pediatric and elderly populations in India and China continue to raise demand. Also, the national health reforms and public insurance schemes facilitate broader access to treatment. The region is becoming a hub for pharmaceutical manufacturing and research, and development.

China is leading the pharyngitis treatment market and is poised to have a significant share. Recent reforms by NMPA have expedited the approval of domestically manufactured antibiotics and diagnostic reagents, which aligns with the 14th Five-Year Plan's focus on controlling infectious diseases and API self-sufficiency in supply chains (NMPA). The growth of the market can also be attributed to the support from the wide-scale manufacturing and availability of various types of treatments. Healthcare reforms in the country have increased coverage and enhanced access to diagnostic tools. 

Europe Market Insights

Europe is set to register significant growth owing to the high occurrence of pharyngitis, mainly during the winter season. The consistent pool of patients sustains robust demand for the antibiotics. The region has well-established healthcare systems and ensures swift patient access. Organizations such as the European Centre for Disease Prevention and Control are implementing stringent guidelines for the prescription. The region has a robust focus on research and development in infectious diseases and is witnessing huge investment.

In Germany, the pharyngitis treatment market is augmented by the presence of strict and evidence-based standards. The advanced healthcare infrastructure in the country and extensive coverage for insurance are also acting as catalysts for the market growth. Additionally, the growth in the market is also increasing due to a high level of healthcare expenditure among the EU countries, valuing USD 542.9 billion in 2022. The country is considered to be a key nation in the world where regulations as well as innovation are converging to foster the growth of the pharyngitis treatment market. Public hospitals have, to a greater extent, embraced rapid diagnostic kits, improving early intervention and secondary complications.

Pharyngitis Treatment Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Key Pharyngitis Treatment Market Players:

    The pharyngitis treatment market is highly competitive and consolidating with major pharmaceutical players. Pfizer, GSK, and Sanofi lead with large portfolios of antibiotics and entrenched global distribution. Manufacturers in India, such as Cipla, Sun Pharma, and Dr. Reddy's, are increasing their share through affordable generics and good API manufacturing. Strategic efforts involve growing in new markets, patent diversification, and joint R&D spending on antimicrobial resistance to provide product differentiation and long-term competitive advantage. Local production and price controls also determine pharyngitis treatment market dynamics.

    Here is a list of key players operating in the pharyngitis treatment market:

    Company Name

    Country of Origin

    Market Share in 2024

    Pfizer Inc.

    USA

    9.7%

    GlaxoSmithKline plc (GSK)

    UK

    8.5%

    Sanofi

    France

    7.1%

    Johnson & Johnson

    USA

    6.8%

    Bayer AG

    Germany

    6.1%

    Abbott Laboratories

    USA

    xx%

    Novartis AG

    Switzerland

    xx%

    Takeda Pharmaceutical Co. Ltd.

    Japan

    xx%

    Reckitt Benckiser Group plc

    UK

    xx%

    Cipla Ltd.

    India

    xx%

    Sun Pharmaceutical Industries

    India

    xx%

    Daewoong Pharmaceutical Co.

    South Korea

    xx%

    Biocon Ltd.

    India

    xx%

    Dr. Reddy’s Laboratories

    India

    xx%

    Astellas Pharma Inc.

    Japan

    xx%

    CSL Limited

    Australia

    xx%

    Hovid Berhad

    Malaysia

    xx%

    Lupin Limited

    India

    xx%

    Mylan (now Viatris Inc.)

    USA

    xx%

    Glenmark Pharmaceuticals

    India

    xx%

    Below are the areas covered for each company in the pharyngitis treatment market:

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis

Recent Developments

  • In March 2024, Pfizer introduced its extended-release azithromycin formulation, Zithromax XR+, targeting patients with bacterial pharyngitis and related upper respiratory tract infections. This innovation was strategically designed to address one of the persistent challenges in pharyngitis management.
  • In August 2024, GlaxoSmithKline (GSK) expanded its well-established Strepsils Advance portfolio with the introduction of a dual-action throat lozenge combining anti-inflammatory and antiseptic properties. This formulation was strategically developed to address both the symptomatic pain and swelling associated with pharyngitis, as well as the bacterial load that often contributes to infection persistence.
  • Report ID: 3124
  • Published Date: Sep 09, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In 2025, the industry size of the pharyngitis treatment is evaluated at USD 2.37 billion.

Pharyngitis Treatment Market size was over USD 2.37 billion in 2025 and is projected to reach USD 2.50 billion by the end of 2037, growing at around 3.9% CAGR during the forecast period i.e., between 2026-2035.

North America dominates the pharyngitis treatment market and is expected to hold a market share of 33.8% by 2035.

Pfizer Inc., GlaxoSmithKline plc (GSK), Sanofi, Johnson & Johnson, Bayer AG, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Co. Ltd., Reckitt Benckiser Group plc, Cipla Ltd., Sun Pharmaceutical Industries, Daewoong Pharmaceutical Co., Biocon Ltd., Dr. Reddy’s Laboratories, Astellas Pharma Inc., CSL Limited, Hovid Berhad, Lupin Limited, Mylan (now Viatris Inc.), Glenmark Pharmaceuticals.

Pharyngitis Treatment Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos